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Absence of RAS and p53 mutations in thyroid
carcinomas of children after Chernobyl in contrast to
adult thyroid tumours
B Suchy, V Waldmann, S Klugbauer and HM Rabes
Institute of Pathology, University of Munich, Thalkirchner Str. 36, D-80337 Munich, Germany
Summary Thyroid carcinomas of an additional series of 34 children exposed to radioactive fall-out afterthe Chernobyl reactor accident were
analysed for mutations in the H-, K- and N-RAS and the p53 gene. Allele-specific oligonucleotide hybridization, single-strand conformation
polymorphism (SSCP) and direct sequencing did not disclose mutations in codons 12, 13 and 61 of RAS genes nor mutations in exons 5, 7
and 8 of p53. Considering the recently reported high prevalence of RET rearrangements of the PTC3 type in childhood tumours after
Chernobyl (Klugbauer et al, 1995, Oncogene 11: 2459-2467), it follows that RET rearrangements are the most relevant molecular aberration
in these radiation-induced tumours. RAS or p53 mutations do not play a role in childhood thyroid carcinogenesis after Chernobyl.
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The incidence of thyroid carcinomas increased steeply in children
exposed to radioactive fall-out after the Chemobyl reactor accident
(Baverstock et al, 1992; Kazakov et al, 1992). Papillary thyroid
carcinomas (PTC), including solid and follicular variants, predom-
inate (Furmanchuk et al, 1992; Nikiforov and Gnepp, 1994). In
adult thyroid carcinomas, genetic changes have been reported, e.g.
mutations ofRAS,p53 and GSP, as well as c-RET rearrangements
and c-MET overexpression (for review see Wynford-Thomas,
1993; Takahashi, 1995; Williams, 1995; Pierotti et al 1996). These
genetic alterations observed in adult thyroid carcinomas need to be
looked for in thyroid tumours that have developed in children after
the Chemobyl accident. Recent studies in our laboratory revealed
that RET rearrangement is a highly prevalent molecular alteration
in these tumours. It has been found in about two-thirds ofthe cases
analysed (Klugbauer et al, 1995; Rabes and Klugbauer, 1997). This
has been confirmed by others (Fuggazola et al, 1995; Nikiforov et
al, 1997). However, information about other genetic changes is
scarce. In a report on the RAS mutation status of33 papillary carci-
nomas of children after Chemobyl that were analysed by single-
strand conformation polymorphism (SSCP), RAS gene mutations
were not found. In the same tumours,just onep53 missense muta-
tion (codon 160) was observed (Nikiforov et al, 1996). With
respect to the G,a gene, direct sequencing of exons 8 and 9
comprising the critical codons 201 and 227 did not disclose any
mutations (Waldmann and Rabes, 1997).
The possibility cannot be dismissed that RET rearrangement,
obviously an important molecular alteration in thyroid carcinomas
of radiation-exposed children after Chernobyl, might be effective
only in connection with other gene mutations that have been
described for thyroid cancer of adults. In the present communica-
tion, we report the results ofa mutation analysis ofRAS andp53 in
Received 16 June 1997
Revised27August 1997
Accepted 18August 1997
Correspondence to: HM Rabes
another large series of thyroid carcinomas that developed in chil-
dren from Belarus early after the Chernobyl reactor accident to
broaden the basis for a molecular evaluation of critical lesions in
this most important cohort ofhuman childhood cancers.
MATERIALS AND METHODS
Paraffin-embedded material from thyroid carcinomas and metastases
of a total of 34 children was available. The children underwent
thyroidectomy at the Department of Surgery, Minsk State Medical
Institute and Center of Thyroid Cancer, Minsk, Belarus, after the
Chemobyl reactor accident. Paraffin blocks of the tumours were
obtained in June 1992. From the paraffin blocks, serial sections were
cut for microscopic evaluation and for polymerase chain reaction
(PCR) amplification ofcritical parts ofthe RASgenes andp53.
In H&E-stained sections (3,m), areas that preferentially
contained tumour cells and tumour-free areas ofnormal tissue were
marked. In unstained 8-jim paraffin serial sections, congruent areas
were scraped off separately, deparaffinized in xylene, washed in
ethanol, boiled for 30-40 min and used for PCR. After denaturation
for 10 min at 96°C, 40 amplification cycles were performed in a
thermal cycler (Perkin-Elmer-Cetus) with Taq DNA polymerase
(Boehringer, Germany) and PCR buffer (tenfold: Tris-HCl,
100 mmol -'; magnesium chloride, 15 mmol 1-1; potassium chloride,
500 mmol 1'; gelatin, 1 mg ml-'; pH 8.3, at 20°C), denaturation for
1 min at 95°C, primer annealing for 2 min at 3°C lower than tm
(melting temperature), and primer extension for 2 min at 72°C.
Purity of the PCR products was checked by 10% acrylamide gel
electrophoresis.
The primers used for PCR amplification of sequences flanking
RAS codon 12/13 and 61 were exactly as reported by Verlaan-de
Vries et al (1986) and Tada et al (1990). Thep53 primers used for
PCR amplification ofexon 5, 7 and 8 were chosen according to the
sequence data given by Buchman et al (1988).
Allele-specific oligonucleotide hybridization on nylon filters was
performed in a dot-blot apparatus as described previously in detail
(Rabes et al, 1990; Suchy et al, 1992; Rabes and Suchy, 1995).
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Figure 1 Examples of a dot-blot hybridization analysis of RAS mutations in PCR-amplified DNA from paraffin-embedded material of childhood carcinomas
from Belarus. Analysis of H-RAS codon 61 - rows 1-3, position of samples from left to right: row 1, 33 tumour (case 24426), 33 normal, 34 tumour (25415), 34
normal; row 2, 35 tumour (27085), 35 normal, 38 tumour (27561), 38 normal; row 3, 32 normal (23492), 36 tumour (27111), 37 tumour (27532), 39 tumour
(27998). (A) hybridization with the wild-type RAS probe (CAG, Gln). (B) Hybridization with probe for CGG (Arg) mutation. (C) hybridization with probe for MG
(Lys) mutation. Analysis of K-RAS codon 61 - rows 4-7, position of samples from left to right: row 4, 36 tumour, 16 normal (16739), 42 tumour (6133), 35
tumour, 33 tumour, 26 tumour (21496); row 5, 37 tumour, 20 tumour (19348), 42 normal, 35 normal, 33 normal, 29 normal (16483); row 6, 39 tumour, 21 tumour
(19320), 44 tumour, 38 tumour, 30 tumour (22274); row 7, negative control, 22 tumour (19297), 44 tumour, 38 normal, 34 normal, 30 normal. (D) wild-type
hybridization for CAA (Gin). (E) Hybridization with probe for CCA (Pro) mutation. (F) hybridization with probe for CGA (Arg) mutation
Allele-specific oligonucleotides for the dot-blot hybridization were
according to Verlaan-de Vries et al (1986) and Tada et al (1990): H-
RAS, codon 61, 5'-GTACTCCTCCTGGCCGGCC-3' (Gln, wild
type), -CCG- (Arg), -CTT- (Lys); K-RAS, codon 61, 5'-
CTCCTCTTGACCTGCTG-TG-3' (Gln, wild type), -TGG- (Pro), -
TCG- (Arg); N-RAS, codon 61, 5'-GATACAGCTG-GACAAGAAG-
3' (Gln, wild type), -GAA- (Glu), -AAA- (Lys), -CTA- (Leu), -CCA-
(Pro), -CGA- (Arg), -CAT- (His), -CAC-(His).
Direct sequencing of PCR products was performed after purifi-
cation using spin columns (Promega) by the dideoxy method
(Sanger et al, 1977) with [32P] dATP (Amersham-Buchler,
Braunschweig, Germany) using the T7-Sequencing Kit
(Pharmacia, Freiburg, Germany) as described (Klugbauer et al,
1995). One of the two flanking primers that had been selected for
PCR was used for direct sequencing.
SSCP analyses (Orita et al, 1989) were performed using 32p_
labelled PCR products after 95% formamide denaturation and
electrophoresis either in 10% acrylamide or with Hydrolink-MDE
gel (Soto and Sukumar, 1992) at 4°C or 10°C. Some gels were run
in 3% glycerol. Each sample was studied, at least, at two different
temperatures or with glycerol. Samples that showed mobility shifts
were subjected to direct sequencing.
Primers and analytical oligonucleotides were synthesized in an
Applied Biosystems Synthesizer (381A) or were purchased from
Pharmacia, MWG or Stratagene. The exact sequence ofall primers
used for this study are available on request.
RESULTS
In 44 tumour and metastasis samples evaluated either by allele-
specific oligonucleotide hybridization or direct sequencing, muta-
tions were not observed at the critical codons 12, 13 or 61 ofeither
H-, K- or N-RAS. Examples of allele-specific oligonucleotide
hybridization are given in Figure 1. At other codons, aberrations
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Figure 2 Direct sequencing of H-RAS exon 1 for mutation analysis of
codons 12 and 13 in PCR-amplified material from paraffin-embedded
childhood thyroid tumours from Belarus. A GGC to AGC (Gin to Ser)
mutation is found in codon 15 of tumour 41 (case 21445) (arrow). Tumour 33
(case 24426), but not the normal tissue of the same patient, shows a silent
mutation (GTG to GTA, Val to Val) in codon 14 (arrow)
from the wild type were found in two tumour samples. A solid
variant of a papillary carcinoma (no. 24426) showed a silent base
exchange (valine to valine) in H-RAS, codon 14 at the third posi-
tion [CAC (GTG) to CAT (GTA)], with the wild-type allele CAC
(GTG) still present (Figure 2). The normal sequence CAC (GTG)
is found in the surrounding normal tissue.
The second aberration was found in tumour No 21445, a lymph
node metastasis of a papillary thyroid carcinoma with a missense
mutation at the first position of H-RAS codon 15, CCG to TCG
(GGC to AGC), which leads to a glycine to serine exchange. The
wild-type allele is still present in the sequencing gel (Figure 2). In
none of the other 58 direct-sequencing runs of exon 1 ofH-, K- or
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Figure 3 SSCP of PCR-amplified DNA fragments for analysis of p53
mutations in exon 7 from paraffin-embedded material from childhood thyroid
carcinomas from Belarus. Tumour samples no. 33 (case 24426), 38 (27561),
five (8421), nine (11892), 35 (27085), 37 (27532), 43 (4264). Samples for
which mobility shifts could not be completely excluded, e.g. tumour 5, were
subjected to direct sequencing
N-RAS nor in the 81 allele-specific oligonucleotide hybridizations
for codon 61 were any further aberrations from normal found in
the tumour samples.
p53 mutation hot spots ofexons 5, 7 and 8, for which mutations
have been described in anaplastic thyroid carcinomas of adults,
were evaluated by SSCP in a total of 22 samples (exon 8, 19
tumour samples). Analyses in different test systems gave no indi-
cation of the presence of mutations in the tumours. Examples are
given in Figure 3. Samples for which a mobility shift in the SSCP
could not be ruled out completely were directly sequenced, but no
evidence for mutations was obtained (Figure 4). p53 mutations at
the investigated exons did not occur in these childhood thyroid
carcinomas.
DISCUSSION
The complete lack of RAS mutations at the critical codons 12, 13,
or 61 and the absence ofp53 mutations in thyroid tumours of the
Chemobyl-afflicted children contrasts with molecular alterations
found in sporadic thyroid carcinomas of adults, which show RAS
mutations in a considerable number ofcases (Lemoine et al, 1988,
1989; Wright et al, 1989, 1991; Namba et al, 1990, Suarez et al,
1990; Karga et al, 1991; Shi et al, 1991; Hara et al, 1994; Manenti
et al, 1994; Challeton et al, 1995). The single case of a missense
mutation in our series with a glycine to leucine exchange concems
codon 15 ofH-RAS. A mutation at this site does not interfere with
GTPase activity orprotein binding capacity ofp2lras. This andthe
silent mutation (val-val) found at codon 14 of H-RAS seem to
reflect the clonality of these tumours. p53 mutations have only
been found in adult thyroid carcinomas of the anaplastic type (Ito
et al, 1992; Nakamura et al, 1992; Fagin et al, 1993; Ho et al,
1996). Childhood thyroid carcinomas after Chemobyl are
predominantly of the papillary type (Furmanchuk et al, 1992;
Nikifirov and Gnepp, 1994). Thus, the absence ofp53 mutations
is not unexpected.
Recently, we reported a high prevalence ofRET rearrangements
in thyroid carcinomas ofchildren after the Chemobyl reactor acci-
dent. ELE/RET (PTC3) is the predominant type of rearrangement
(Fugazzola et al, 1995; Klugbauer et al, 1995, 1996; Nikiforov et
al, 1997; Rabes and Klugbauer, 1997). Missense mutations ofRAS
or p53 may certainly occur in cells of radiation-exposed thyroid
glands but will probably not show up in a tumour because the
clonogenic potential ofthyrocytes bearing RAS orp53 mutations is
apparently less penetrant than that ofcells with RETrearrangement
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Figure 4 DNA base sequencing of p53, exon 7, of tumour no. 5 (case
8421), for which a mobility shift in the SSCP was suspected. First codon,
open triangle; last codon of exon 7, closed triangle. Mutations were not
observed
after radiation-induced DNA double-strand break and recombina-
tional repair.
This second communication after the earlier report by Nikiforov
et al (1996) appearsjustified as the collection ofmore data is impor-
tant for evaluation, on abroad basis, ofthe critical molecular events
in this cohort of radiation-induced tumours. In principle, the data
presented here, which were obtained from another set of tumours,
confirm the results of Nikiforov et al (1996). However, the possi-
bility cannot be excluded that thyroid carcinomas that develop in
exposed areas afterlongerlatency periods may exhibit a wider spec-
trum of genetic changes, including RAS or p53 mutations. It is
tempting to predict that these later appearing tumours will less
frequently show RET rearrangements because the probability of
DNA double-strand breaks decreases with lowering dose ofirradia-
tion. Instead, other less penetrant molecular alterations, e.g. in RAS
orp53 genes, or a combination ofvarious genetic changes may take
the lead in the development of thyroid carcinomas occurring late
after Chemobyl. At present, RET rearrangements ofthe PTC3 type
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are obviously ahighly significant genetic aberration in thyroid carci-
nomas of young children exposed to radioactive fall-out. All other
genetic changes known from adult thyroid carcinomas, RAS andp53
in particular, appear to be irrelevant at this stage.
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